NUSAP1 promotes the metastasis of breast cancer cells via the AMPK/PPARγ signaling pathway

Xu, Li; Zeng, Xiaohong; Wu, Zhenru; Wang, Yu; Wang, Yao; Yang, Jiqiao; Wu, Hao; Xie, Yanyan; Liang, Faqing; Lv, Qing; Du, Zhenggui

doi:10.21037/atm-21-5517

Cited by 12 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our fndings are like those of Qiu et al Tey reported higher NUSAP1 expression in tumors than in adjacent healthy tissue and an inverse correlation between NUSAP1 expression and OS in BC patients. Tese fndings were corroborated in a BALB/c-nu mouse model in which they determined the involvement of NUSAP1 in tumor proliferation, migration, and invasion [18]. Finally, NUSAP1 has been proposed as a carcinogenic element whose overexpression would help tumor progression in triple-negative BC cells, participating in the epithelialmesenchymal transition and the Wnt/β-catenin pathways [17].…”

Section: Ccdc8 Ccnb1 Fhl1 Nusap1 Rrm2 and Ube2c)mentioning

confidence: 85%

See 1 more Smart Citation

NUSAP1 and PCLAF (KIA0101) Downregulation by Neoadjuvant Therapy is Associated with Better Therapeutic Outcomes and Survival in Breast Cancer

Magallanes-Garza

Santuario‐Facio

Lira-Albarrán

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Purpose. To evaluate whether changes in genomic expression that occur beginning with breast cancer (BC) diagnosis and through to tumor resection after neoadjuvant chemotherapy (NCT) reveal biomarkers that can help predict therapeutic response and survival. Materials and Methods. We determined gene expression profiles based on microarrays in tumor samples from 39 BC patients who showed pathologic complete response (pCR) or therapeutic failure (non-pCR) after NCT (cyclophosphamide-doxorubicin/epirubicin). Based on unsupervised clustering of gene expression, together with functional enrichment analyses of differentially expressed genes, we selected NUSAP1, PCLAF, MME, and DST. We evaluated the NCT response and the expression of these four genes in BC histologic subtypes. In addition, we study the presence of tumor-infiltrating lymphocytes. Finally, we analyze the correlation between NUSAP1 and PCLAF against disease-free survival (DFS) and overall survival (OS). Results. A signature of 43 differentially expressed genes discriminated pCR from non-pCR patients (|fold change >2|, false discovery rate <0.05) only in biopsies taken after surgery. Patients achieving pCR showed downregulation of NUSAP1 and PCLAF in tumor tissues and increased DFS and OS, while overexpression of these genes correlated with poor therapeutic response and OS. These genes are involved in the regulation of mitotic division. Conclusions. The downregulation of NUSAP1 and PCLAF after NCT is associated with the tumor response to chemotherapy and patient survival.

show abstract

Section: Ccdc8 Ccnb1 Fhl1 Nusap1 Rrm2 and Ube2c)mentioning

confidence: 85%

“…NUSAP1 is involved in cell proliferation and migration, and PCLAF participates in cell cycle control and apoptosis [ 15 , 16 ]. Overexpression of these genes has each been correlated with tumor progression and metastasis [ 17 , 18 ]. Downregulation of MME is associated with tumor recurrence and metastasis [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

NUSAP1 and PCLAF (KIA0101) Downregulation by Neoadjuvant Therapy is Associated with Better Therapeutic Outcomes and Survival in Breast Cancer

Magallanes-Garza

Santuario‐Facio

Lira-Albarrán

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…PAPOLA (Komini et al 2021) is observed to be associated with proliferation, which is an ideal candidate target from prior research as it is overexpressed by 119% in triple-negative breast tumors. Likewise, BIRC2 (Samanta et al 2020), NUSAP1 (De Luca, Romano, and Bucci 2021), ATP6V1G1 (Qiu et al 2021), PTGES3 (Adekeye et al 2022), that are overexpressed by 118%, 111%, 117%, and 118% respectively, are potential biomarkers in breast can-cer, have also been overexpressed in iCCA proliferation, giving the researchers an opportunity for drug re-purposing. CCNY (Liu et al 2016), and ZFP36L1 (Suk et al 2018) are potential biomarkers in Ovarian cancer and are also overexpressed by 127% and 123%, respectively.…”

Section: Results and Experimental Analysismentioning

confidence: 99%

GMRC: Gene Median Ratio Clustering Algorithm to Rank Clusters and Identify Driver Genes in Intrahepatic Cholangiocarcinoma

Puri

Arora

Tanwar

et al. 2022

Preprint

View full text Add to dashboard Cite

Intrahepatic Cholangiocarcinoma (iCCA) is an asymptomatic malignancy of the bile ducts in the liver. The research is predicated on the assumption that a disease is a cluster of genes interacting in a regulatory network and a few driver genes regulating the network. Keeping this in mind, the paper proposes a Gene Median Ratio Clustering (GMRC) algorithm to independently rank the clusters and identify driver genes by hybridizing gene-median ratio (GMR) and em gene cluster network GCN. GMR then employs the Poisson distribution to translate right-skewed data into the Normal distribution and the Anscombe transformation to eliminate data noise and determine the median difference in gene concentration between distinct disease stages. Additionally, hierarchical clustering is separately applied to raw data for gene clustering based on the RNA sequence count. In the process, GMRC is evaluated over the GSE32225 dataset of 155 patients to extract 12 clusters network for proliferation patients.

show abstract

“…In gastric cancer, it has been found that the upregulation of NUSAP1 is associated with unfavorable clinical outcomes, and NUSAP1 depletion impairs its oncogenic properties in vitro and in a xenograft model [9,24]. In breast cancer, NUSAP1 is overexpressed and can boost proliferation, migration, and invasion and metastasis of breast cancer cells by activating the AMPK/PPARγ and Wnt/β-catenin/EMT signaling pathway [10,25,26]. The high expression of NUSAP1 has also been found in bladder cancer, and its up-regulation signi cantly promoted the proliferation and inhibited the apoptosis of bladder cancer cells possibly through the TGF-β Signaling Pathway [11,27,28].…”

Section: Discussionmentioning

confidence: 99%

“…Recently, the oncogenic role of NUSAP1 in various cancers have been identi ed. Studies show that high expression of NUSAP1 has been found in pancreatic cancer [8], gastric cancer [9], breast cancer [10], bladder cancer [11], colon cancer [12], all of which correlated to a poorer prognosis. In the perspective of lung cancer, it has been showed that NUSAP1 promotes NSCLC progression [13], and its knockdown can inhibit cell growth and metastasis of NSCLC [14].…”

Section: Introductionmentioning

confidence: 99%

NUSAP1 is a Prognostic Biomarker and Correlated to Immune Infiltration in Lung Adenocarcinoma

Wang¹,

Yin²,

Zhou³

et al. 2023

Preprint

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer, the leading cancer-related death worldwide. Nucleolar spindle-associated protein 1 (NUSAP1) is a microtubule-associated protein firstly been found in proliferating cells, and recently known to be involved in carcinogenesis. However, the role of NUSAP1 in LUAD has yet to be explored. In current study, we used GEO datasets to identified a group of hub genes in LUAD, used Kaplan-Meier analysis to explore their impact on prognosis. NUSAP1 was chosen based on clinical relevance and literature searching results. The expression level of NUSAP1 was explored using TIMER, TCGA-LUAD database, human protein atlas (HPA), and verified by immunohistochemistry. Genes co-expressed with NUSAP1 were identified and GO/KEGG were performed to identify its biological functions. The impact of NUSAP1 on immune infiltration was investigated in TIMER. The correlation between NUSAP1 expression and clinical relevance were identified using diagnostic receiver operating characteristic (ROC) curves, nomogram model, and cox regression analysis. Immunohistochemistry was used to confirm the over-expression of NUSAP1 in LUAD and its correlation with MDSC. In short, we found a group of 20 hub genes in LUAD, all of which were differentially expressed in LUAD and most of them predicted a poor prognosis. NUSAP1 was upregulated in LUAD and most of the malignancies and correlated to multiple clinical parameters like pathological stage, N stage, M stage. Co-expressed genes and GO/KEGG showed that NUSAP1 mainly participates in cell cycle. Immune infiltration study demonstrated that NUSAP1 correlated to multiple immune cells, particularly myeloid-derived suppressor cell (MDSC). PrognoScan database verified the prognostic value of NUSAP1. Lastly, high expression of NUSAP1 and its correlation with MDSC was testified by immunohistochemistry. In summary, we found NUSAP1 were upregulated in LUAD and can serve as potential biomarker to indicate prognosis of LUAD.

show abstract

NUSAP1 promotes the metastasis of breast cancer cells via the AMPK/PPARγ signaling pathway

Cited by 12 publications

References 34 publications

NUSAP1 and PCLAF (KIA0101) Downregulation by Neoadjuvant Therapy is Associated with Better Therapeutic Outcomes and Survival in Breast Cancer

NUSAP1 and PCLAF (KIA0101) Downregulation by Neoadjuvant Therapy is Associated with Better Therapeutic Outcomes and Survival in Breast Cancer

GMRC: Gene Median Ratio Clustering Algorithm to Rank Clusters and Identify Driver Genes in Intrahepatic Cholangiocarcinoma

NUSAP1 is a Prognostic Biomarker and Correlated to Immune Infiltration in Lung Adenocarcinoma

Contact Info

Product

Resources

About